GlobeNewswire·Jul 27, 2026, 7:00 AM ET

VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb

VRXA OABI

VERAXA Biotech AG (NASDAQ: VRXA) announced the advancement of its bispecific ADC program VXA-222 following the successful conclusion of a key technical milestone in its alliance with OmniAb, Inc. (NASDAQ: OABI).
VXA-222 utilizes an "AND-gate" logic design to target two different antigens on solid tumors using a single molecule.
The collaboration, established in May 2025, combined OmniAb's transgenic antibody discovery solutions, including OmniClic™, with VERAXA's proprietary ADC linker technology & conjugation expertise.
OmniAb utilized its in vivo affinity maturation technology to source high-quality human antibody leads, while VERAXA is responsible for establishing the lead candidate, applying its linker technology, & conducting in vitro & in vivo validation.
Under the agreement terms, VERAXA holds exclusive rights to develop & commercialize products incorporating OmniAb-derived antibodies, with OmniAb entitled to a share of specified revenue from those products.
Christoph Erkel, Ph.D., Chief Scientific Officer of VERAXA, stated the partnership united complementary technologies to create a best-in-class bispecific ADC candidate for solid tumor indications.
Bill Harriman, Ph.D., Senior Vice President at OmniAb, highlighted the productive collaboration & the complementary strengths of both companies' scientific & business teams.
VERAXA is building a pipeline of next-generation antibody-based therapeutics, including bispecific T cell engagers & BiTAC formats, based on breakthroughs from the European Molecular Biology Laboratory (EMBL).
The press release includes standard forward-looking statements regarding future activities, events, & developments, noting inherent risks & uncertainties that could cause actual outcomes to differ from expectations.